Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPR277 topical ointment in adult Netherton syndrome
NL-OMON40034Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of LM-030 in Netherton syndrome (NS) (2 arms), sponsored by Novartis. Primary endpoints: Total lesional sign score and Safety and tolerability. Started Oct 2013; status: active, not recruiting.
02
Drugs
LM-030
03
Conditions
Netherton syndrome (NS)
Beyond the preview
Go deeper on NL-OMON40034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40034.